{"indexed":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T15:57:54Z","timestamp":1574351874491},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"URL":"http:\/\/www.springer.com\/tdm","start":{"date-parts":[[2010,10,30]],"date-time":"2010-10-30T00:00:00Z","timestamp":1288396800000},"delay-in-days":0,"content-version":"tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s10067-010-1611-3","type":"article-journal","created":{"date-parts":[[2010,11,3]],"date-time":"2010-11-03T09:14:12Z","timestamp":1288775652000},"page":"149-150","source":"Crossref","is-referenced-by-count":1,"title":"Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget\u2019s disease of bone","prefix":"10.1007","volume":"30","author":[{"given":"Stergios A.","family":"Polyzos","sequence":"first","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2010,10,30]]},"reference":[{"key":"1611_CR1","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s10067-010-1486-3","volume":"29","author":"M Maricic","year":"2010","unstructured":"Maricic M (2010) The role of zoledronic acid in the management of osteoporosis. Clin Rheumatol 29:1079\u20131084","journal-title":"Clin Rheumatol"},{"key":"1611_CR2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"1611_CR3","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/AOG.0b013e3181bdce0a","volume":"114","author":"M McClung","year":"2009","unstructured":"McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL (2009) Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol 114:999\u20131007","journal-title":"Obstet Gynecol"},{"key":"1611_CR4","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/jbmr.103","volume":"25","author":"A Grey","year":"2010","unstructured":"Grey A, Bolland M, Wattie D, Horne A, Gamble G, Reid IR (2010) Prolonged anti-resorptive activity of zoledronate\u2014a randomized controlled trial. J Bone Miner Res 25:2251\u20132255","journal-title":"J Bone Miner Res"},{"key":"1611_CR5","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1210\/jc.2008-2241","volume":"94","author":"A Grey","year":"2009","unstructured":"Grey A, Bolland MJ, Wattie D, Horne A, Gamble G, Reid IR (2009) The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab 94:538\u2013544","journal-title":"J Clin Endocrinol Metab"},{"key":"1611_CR6","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","volume":"353","author":"IR Reid","year":"2005","unstructured":"Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget\u2019s disease. N Engl J Med 353:898\u2013908","journal-title":"N Engl J Med"},{"key":"1611_CR7","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1359\/jbmr.070704","volume":"22","author":"D Merlotti","year":"2007","unstructured":"Merlotti D, Gennari L, Martini G, Valleggi F, De PV, Avanzati A, Nuti R (2007) Comparison of different intravenous bisphosphonate regimens for Paget\u2019s disease of bone. J Bone Miner Res 22:1510\u20131517","journal-title":"J Bone Miner Res"},{"key":"1611_CR8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1359\/jbmr.061001","volume":"22","author":"D Hosking","year":"2007","unstructured":"Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR (2007) Long-term control of bone turnover in Paget\u2019s disease with zoledronic acid and risedronate. J Bone Miner Res 22:142\u2013148","journal-title":"J Bone Miner Res"},{"key":"1611_CR9","first-page":"S358","volume":"24","author":"IR Reid","year":"2009","unstructured":"Reid IR, Lyles K, Su G et al (2009) Long-term efficacy of zoledronic acid compared with risedronate in Paget\u2019s disease. J Bone Miner Res 24:S358\u2013S358","journal-title":"J Bone Miner Res"},{"key":"1611_CR10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00774-008-0852-6","volume":"26","author":"A Avramidis","year":"2008","unstructured":"Avramidis A, Polyzos SA, Moralidis E, Arsos G, Efstathiadou Z, Karakatsanis K, Grollios G, Kita M (2008) Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget\u2019s disease of bone. J Bone Miner Metab 26:635\u2013641","journal-title":"J Bone Miner Metab"},{"key":"1611_CR11","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1055\/s-0029-1233491","volume":"41","author":"SA Polyzos","year":"2009","unstructured":"Polyzos SA, Anastasilakis AD, Efstathiadou Z, Kita M, Litsas I, Avramidis A, Arsos G, Moralidis E, Gerou S, Pavlidou V, Papatheodorou A, Terpos E (2009) The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin and RANKL in patients with Paget\u2019s disease of bone. Horm Metab Res 41:846\u2013850","journal-title":"Horm Metab Res"},{"key":"1611_CR12","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00198-008-0629-8","volume":"19","author":"JP Devogelaer","year":"2008","unstructured":"Devogelaer JP, Bergmann P, Body JJ, Boutsen Y, Goemaere S, Kaufman JM, Reginster JY, Rozenberg S, Boonen S (2008) Management of patients with Paget\u2019s disease: a consensus document of the Belgian Bone Club. Osteoporos Int 19:1109\u20131117","journal-title":"Osteoporos Int"},{"key":"1611_CR13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(08)61035-1","volume":"372","author":"SH Ralston","year":"2008","unstructured":"Ralston SH, Langston AL, Reid IR (2008) Pathogenesis and management of Paget\u2019s disease of bone. Lancet 372:155\u2013163","journal-title":"Lancet"},{"key":"1611_CR14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1359\/jbmr.090709","volume":"25","author":"AL Langston","year":"2010","unstructured":"Langston AL, Campbell MK, Fraser WD, MacLennan GS, Selby PL, Ralston SH (2010) Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget\u2019s disease of bone. J Bone Miner Res 25:20\u201331","journal-title":"J Bone Miner Res"}],"container-title":"Clinical Rheumatology","original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-010-1611-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-010-1611-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-010-1611-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:51:45Z","timestamp":1559119905000},"score":1.0,"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,30]]},"references-count":14,"journal-issue":{"published-print":{"date-parts":[[2011,1]]},"issue":"1"},"alternative-id":["1611"],"URL":"http:\/\/dx.doi.org\/10.1007\/s10067-010-1611-3","relation":{"cites":[]},"ISSN":["0770-3198","1434-9949"],"subject":["Rheumatology","General Medicine"],"container-title-short":"Clin Rheumatol"}